Literature DB >> 26768560

Statistics and logistics: Design of Ebola vaccine trials in West Africa.

Martha Nason1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26768560     DOI： 10.1177/1740774515620612

Source DB:  PubMed          Journal:  Clin Trials        ISSN： 1740-7745            Impact factor:   2.486


× No keyword cloud information.
  6 in total

Review 1.  Design of vaccine efficacy trials during public health emergencies.

Authors:  Natalie E Dean; Pierre-Stéphane Gsell; Ron Brookmeyer; Victor De Gruttola; Christl A Donnelly; M Elizabeth Halloran; Momodou Jasseh; Martha Nason; Ximena Riveros; Conall H Watson; Ana Maria Henao-Restrepo; Ira M Longini
Journal:  Sci Transl Med       Date:  2019-07-03       Impact factor: 17.956

2.  Quantifying Efficiency Gains of Innovative Designs of Two-Arm Vaccine Trials for COVID-19 Using an Epidemic Simulation Model.

Authors:  Rob Johnson; Chris Jackson; Anne Presanis; Sofia S Villar; Daniela De Angelis
Journal:  Stat Biopharm Res       Date:  2021-07-30       Impact factor: 1.452

3.  An evidence mapping and analysis of registered COVID-19 clinical trials in China.

Authors:  Liming Lu; Fan Li; Hao Wen; Shuqi Ge; Jingchun Zeng; Wen Luo; Lai Wang; Chunzhi Tang; Nenggui Xu
Journal:  BMC Med       Date:  2020-06-01       Impact factor: 8.775

4.  Challenges of evaluating and modelling vaccination in emerging infectious diseases.

Authors:  Zachary J Madewell; Natalie E Dean; Jesse A Berlin; Paul M Coplan; Kourtney J Davis; Claudio J Struchiner; M Elizabeth Halloran
Journal:  Epidemics       Date:  2021-10-05       Impact factor: 5.324

5.  Choices in vaccine trial design in epidemics of emerging infections.

Authors:  Rebecca Kahn; Annette Rid; Peter G Smith; Nir Eyal; Marc Lipsitch
Journal:  PLoS Med       Date:  2018-08-07       Impact factor: 11.069

6.  Response adaptive intervention allocation in stepped-wedge cluster randomized trials.

Authors:  Michael J Grayling; James M S Wason; Sofía S Villar
Journal:  Stat Med       Date:  2022-01-21       Impact factor: 2.497
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.